The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
625
SAFETY AND EFFICACY OF INEBILIZUMAB IN IGG4 RELATED DISEASE IN PARTICIPANTS WITH PANCREATIC AND BILIARY INVOLVEMENT: RESULTS FROM THE PHASE 3 MITIGATE TRIAL
Date
May 5, 2025
Explore related products in the following collection:
